|Articles|June 15, 2002
- BioPharm International-06-01-2002
- Volume 15
- Issue 6
Inside Washington: Safety, Risk, and Biotechnology Regulation
Author(s)Jill Wechsler
by Jill Wechsler Concerns about product safety and stiffer FDA regulation of manufacturers may be drying up the biotech pipeline
Advertisement
Articles in this issue
over 23 years ago
Negotiating and Structuring Strategic Alliancesover 23 years ago
Finding Funding in Biotechnology: Keeping the Companies Aliveover 23 years ago
Stem Cells and Xenotransplantation: Ethics, Patents, and Politicsover 23 years ago
Unlocking the Value of R&D: Managing the Risksover 23 years ago
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesover 23 years ago
Criminal Penalties for Theft of Biological MaterialNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
2
How Mitigation and Maintenance Protect Against Future Risk
3
FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline
4
Navigating the Next Wave of Biopharma Manufacturing Innovation
5
